ViiV’s Rukobia wins EU authorisation to treat multidrug-resistant HIV
Rukobia is a first-in-class HIV attachment inhibitor
Read More
Tag: Rukobia
FDA approves ViiV’s novel HIV treatment Rukobia
60% of heavily treatment-experienced patients achieved undetectable viral load after taking the drug
Read More
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
